Header Logo

Subcutaneous versus intravenous daratumumab in multiple myeloma - Authors' reply.

Mateos MV, Usmani SZ. Subcutaneous versus intravenous daratumumab in multiple myeloma - Authors' reply. Lancet Haematol. 2020 08; 7(8):e559.

View in: PubMed